10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

VPAC2 / VIPR2 Antibody (C-Terminus)
Rabbit Polyclonal Antibody
Catalog # ALS10327

Specification

VPAC2 / VIPR2 Antibody (C-Terminus) - Product Information

Application	**IHC-P**
Primary Accession	P41587
Reactivity	**Human**
Host	**Rabbit**
Clonality	**Polyclonal**
Calculated MW	**49kDa KDa**
Dilution	**IHC-P~~N/A**

VPAC2 / VIPR2 Antibody (C-Terminus) - Additional Information

Gene ID 7434

Other Names
Vasoactive intestinal polypeptide receptor 2, VIP-R-2, Helodermin-preferring VIP receptor, Pituitary adenylate cyclase-activating polypeptide type III receptor, PACAP type III receptor, PACAP-R-3, PACAP-R3, VPAC2, VIPR2, VIP2R

Target/Specificity
Human VIPR2. BLAST analysis of the peptide immunogen showed no homology with other human proteins.

Reconstitution & Storage
Long term: -70°C; Short term: +4°C

Precautions
VPAC2 / VIPR2 Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures.

VPAC2 / VIPR2 Antibody (C-Terminus) - Protein Information

Name VIPR2 (HGNC:12695)

Synonyms VIP2R

Function
G protein-coupled receptor activated by the neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase- activating polypeptide (ADCYAP1/PACAP) (PubMed:7811244, PubMed:35477937, PubMed:8933357). Binds VIP and both PACAP27 and PACAP38 bioactive peptides with the following order of potency PACAP38 = VIP > PACAP27 (PubMed:<a href="http://www.uniprot.org/citations/35477937"

target="_blank">35477937, PubMed:8933357). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors. Activates cAMP-dependent pathway (PubMed:7811244, PubMed:35477937, PubMed:8933357). May be coupled to phospholipase C.

Cellular Location
Cell membrane; Multi-pass membrane protein

Tissue Location
Expressed in CD4+ T-cells, but not in CD8+ T-cells. Expressed in the T-cell lines Jurkat, Peer, MOLT-4, HSB, YT and SUP-T1, but not in the T-cell lines HARRIS and HuT 78

Volume
50 µl

VPAC2 / VIPR2 Antibody (C-Terminus) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

VPAC2 / VIPR2 Antibody (C-Terminus) - Images



Anti-VPAC2 / VIPR2 antibody IHC of human Pancreas, Carcinoma.

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999



Anti-VPAC2 / VIPR2 antibody IHC of human Breast, Carcinoma.



Anti-VIPR2 antibody ALS10327 IHC of human liver and bile ducts.



Anti-VPAC2 / VIPR2 antibody IHC of human Ovary, Carcinoma.

VPAC2 / VIPR2 Antibody (C-Terminus) - Background

This is a receptor for VIP as well as PACAP-38 and -27, the activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Can be coupled to phospholipase C.

VPAC2 / VIPR2 Antibody (C-Terminus) - References

Svoboda M.,et al.Biochem. Biophys. Res. Commun. 205:1617-1624(1994).
Mackay M.,et al.Genomics 37:345-353(1996).
Wei Y.,et al.J. Neuroendocrinol. 8:811-817(1996).

Lutz E.M.,et al.FEBS Lett. 458:197-203(1999).
Kalnine N.,et al.Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.